-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Caribou Biosciences, a CRISPR genome-editing biomedical company, announced that the company’s innovative allogeneic CAR-T therapy CB-010 is used in the treatment of relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r B-NHL).
CB-010 is an allogeneic anti-CD19 CAR-T cell therapy derived from healthy donor T cells
The usual CRISPR gene editing system uses guide RNA (guide RNA) to mediate the cleavage of specific sites in the genome by the Cas enzyme
Note: The original text has been deleted
Reference materials:
[1] Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.